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Abstract 
Background: Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer death worldwide and is char‑
acterized by numerous genetic mutations. TNM staging is not sufficient for predicting patient outcomes. Addition‑
ally, ESCC shows poor responsiveness to chemotherapy and radiation. Thus, there is an urgent need to find efficient 
therapy targets. Previous ESCC high‑throughput genomic studies have lacked intensive survival analysis, particularly 
for copy number variation (CNV) and the genes involved.
Main body: In the study “Genomic Characterization of Esophageal Squamous Cell Carcinoma Reveals Critical Genes 
Underlying Tumorigenesis and Poor Prognosis” recently published in the American Journal of Human Genetics, we 
comprehensively analyzed the effects of CNVs, mutations, and relative gene expression on patient outcomes. To 
validate our findings for our 67 sequencing samples, we collected a 321‑patient retrospective cohort with detailed 
5‑year follow‑up information and carried out univariate and multivariate survival analyses. In addition, the biological 
functions of the survival predictors in ESCC were investigated both in vitro and in vivo.
Conclusions: We found the independent ESCC survival predictors and potential therapy targets. Nevertheless, the 
effects of numerous low‑frequency mutations need to be explored using larger sample sequencing. Overall, con‑
structing multi‑gene prognostic signatures will remain a great challenge in the future.
Keywords: Esophageal squamous cell carcinoma, Copy number variation, Prognostic analysis
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Esophageal cancer is the eighth most common cancer 
and the sixth leading cause of cancer-related death in the 
world, with approximately 456,000 new cases per year 
globally [1–4]. There are two main esophageal cancer 
histological subtypes: esophageal squamous cell carci-
noma (ESCC) and esophageal adenocarcinoma [5]. ESCC 
accounts for 80% of esophageal cancer cases worldwide, 
and the risk is influenced by environmental factors (alco-
hol consumption and tobacco use) and genetic factors. 
Only 15%–25% ESCC patients survive for 5 years [6, 7].
Although staging of the tumor is important for determin-
ing the therapeutic strategy, it cannot precisely predict prog-
nosis. Thus, a signature for classifying patients as potential 
therapy responders or non-responders would be of great 
clinical use if performed using initial diagnostic biopsies.
The poor responsiveness of ESCC to chemotherapy 
and radiation is a main reason for poor patient out-
comes. Moreover, efficient targeted medicine for ESCC 
treatment is lacking to date. Therefore, the mechanisms 
underlining the poor prognosis of this disease are essen-
tial for finding therapy targets.
Several ESCC high-throughput genomic sequencing stud-
ies have been reported recently [8–11]; however, none has 
comprehensively evaluated both the effects of copy number 
variations (CNVs) and mutations on patient prognosis.
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Main body
In our recent article entitled “Genomic Characterization 
of Esophageal Squamous Cell Carcinoma Reveals Critical 
Genes Underlying Tumorigenesis and Poor Prognosis” 
published in the American Journal of Human Genet-
ics, we reported a high-throughput genomic sequencing 
study of ESCC. By detecting and characterizing somatic 
variants, we comprehensively analyzed the effects of 
CNVs, mutations, and relative gene expression on 
patients’ overall survival (OS). For essential genes, fur-
ther biological experiments were carried out in vitro and 
in vivo. The goal was to identify critical mutations under-
lying the poor prognosis of ESCC and to find potential 
prognosis makers and therapy targets [12].
In the 67 samples comprising the sequencing cohort, 
19,434 mutations were found in exon regions of the 
ESCC genome. Using MutSigCV software [13], tumor 
protein p53 (TP53), cyclin-dependent kinase inhibitor 2A 
(CDKN2A), notch homolog 1, translocation-associated 
(Drosophila) (NOTCH1), and nuclear factor, erythroid 2 
like 2 (NFE2L2) were identified as significantly mutated 
genes. These four genes were then subjected to OS analy-
sis. The results showed that patients harboring NOTCH1 
mutations had a longer lifespan after surgery than those 
without mutations. In addition, using a cohort of inde-
pendent 321 samples, we found that individuals with 
lower NOTCH1 expression had a higher 5-year OS rate 
than those with higher NOTCH1 levels. Multivariate Cox 
regression analysis indicated that after adjustment for 
age, sex, tumor stage, smoking, and alcohol consumption, 
NOTCH1 expression was significantly associated with 
OS. These findings suggest that NOTCH1 might play an 
essential role in ESCC progression.
Compared with mutations, we found much higher fre-
quencies of CNVs in ESCC. To explore their influence 
on survival, both CNVs and expression of the associated 
genes were detected by quantitative polymerase chain 
reaction (qPCR). A number of CNVs and genes were 
found to be associated with poor patient outcomes.
MYB proto-oncogene like 2 (MYBL2), a reported cell 
cycle regulator, showed elevated gene copy numbers in 
70% of the tumors subjected to whole-genome sequenc-
ing. Its transcripts and protein were also overexpressed 
in ESCC compared with adjacent normal tissues. Both 
the gene copy number and expression of MYBL2 showed 
negative effects on individuals’ survival. In  vitro studies 
demonstrated that overexpression of MYBL2 increased 
proliferation in ESCC cell lines.
Non-coding RNA plays an important role in tumo-
rigenesis and development. However, previous compara-
tive genomic hybridization studies mainly focused on 
coding genes. In our study, a CNV-harbored microRNA, 
miR-4707-5p, was found to be significantly overexpressed 
in tumors, and individuals with high miR-4707-5p lev-
els exhibited worse prognosis than those with low miR-
4707-5p levels. An in vitro pilot experiment revealed that 
miR-4707-5p has a strong ability to promote cell migra-
tion and invasion. The pro-metastasis ability of miR-
4707-5p was confirmed in two different mouse tumor 
metastasis models. Furthermore, through mechanism 
studies, we found that miR-4707-5p can decrease E-cad-
herin by targeting adenosine deaminase, RNA specific B1 
(ADARB1), in turn promoting cell metastasis. Therefore, 
the CNV-miR-4707-5p-ADARB1-E-cadherin axis might 
be a target of ESCC therapy.
Interestingly, VANGL planar cell polarity protein 1 
(VANGL1), a novel high-frequency mutant gene that 
we found, showed no association with ESCC prognosis. 
Thus, VANGL1 mutation might play a role only at early 
stages of the neoplastic process.
Although a list of prognosis predictors was found, we 
could not rule out the possibility that low-frequency 
mutations also have an impact on prognosis, at least for 
particular individuals. However, due to the limited sam-
ple size, the association between these low-frequency 
mutant genes and ESCC prognosis could not be analyzed 
in this study. As cancer occurrence and development are 
the result of the participation of multiple genes, a multi-
gene prognostic signature would be more convincing, 
though this is difficult to realize because of the limited 
sample size, low frequency of mutations, and complexity 
of genomic variants.
Conclusions
Through a comprehensive genomic study and gene 
expression analysis, we identified a number of inde-
pendent prognosis predictors. We showed that at least 
two of them, MYBL2 and miR-4707-5p, are involved 
in ESCC cell malignant transformation and might 
be a basis for poor ESCC prognosis. Considering the 
decreasing cost of sequencing, experiments with larger 
sample sizes and more serviceable algorithms would 
help in the future search for a multi-gene prognostic 
signature.
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